Welcome to our dedicated page for Icu Medical SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ICU Medical, Inc. (Nasdaq: ICUI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, together with AI-powered tools to help interpret them. ICU Medical is a medical technology company headquartered in San Clemente, California, and describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings.
ICU Medical files periodic and current reports with the U.S. Securities and Exchange Commission, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. For example, the company has filed Form 8-K reports to furnish press releases announcing its quarterly financial results. These filings provide detail on total revenues, cost of goods sold, gross profit, operating expenses, product line revenues for Consumables, Infusion Systems and Vital Care, net income or loss, cash flows and non-GAAP measures such as adjusted EBITDA and adjusted diluted earnings per share.
On Stock Titan, AI-generated summaries can highlight key elements of ICU Medical’s filings, helping users quickly understand disclosures related to product line performance, restructuring and integration expenses, contract manufacturing, joint ventures such as Otsuka ICU Medical LLC, and the risk factors the company describes in its Form 10-K and subsequent filings. Real-time updates from EDGAR ensure that new ICUI filings, including Forms 10-K, 10-Q, 8-K and other relevant documents, are added as they become available.
The filings page can also be used to review information that underlies the company’s press releases, such as the 8-K items that reference earnings announcements. By combining official SEC documents with AI explanations, this resource helps investors and analysts navigate ICU Medical’s financial reporting, segment disclosures and regulatory communications without having to manually parse every line of each filing.
ICU Medical is asking stockholders to elect seven directors, ratify Deloitte & Touche as auditor, approve executive pay on an advisory basis, and vote on several governance changes at its 2026 virtual annual meeting.
The board seeks amendments to adopt simple majority voting and give stockholders owning at least 25% of shares the right to call special meetings, while recommending against a stockholder proposal for a 10% special meeting right. Pay programs emphasize performance: in 2025, about 86% of named executive officers’ target compensation was variable, driven by Adjusted EBITDA, Free Cash Flow and multi‑year performance‑based RSUs. Despite revenue of $2.23 billion declining 6.3%, Adjusted EBITDA rose to $403.8 million and Adjusted diluted EPS increased to $7.75, supporting 150% of target annual bonuses. CEO total 2025 compensation was about $6.45 million, with base salary held flat and significant equity awards tied to multi‑year financial goals.
The Vanguard Group filed an amendment to its Schedule 13G reporting zero shares of Common Stock of ICU Medical Inc. The filing states Vanguard underwent an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The filing lists 0 shares and 0% ownership and is signed by Ashley Grim on 03/27/2026.
ICU Medical Inc. director Donald Abbey reported an other-type share transfer involving 704 shares of Common Stock. The transaction occurred on March 25, 2026 at a stated price of $0.00 per share and was categorized as an "other acquisition or disposition."
According to the footnote, the shares were transferred pursuant to a domestic relations order, and the reporting person no longer has a reportable beneficial interest in the transferred shares. Following this non-market, personal-transfer event, Abbey directly holds 4,046 shares of ICU Medical common stock.
ICU Medical, Inc. will hold its virtual Annual Meeting on May 13, 2026; the record date for voting is March 20, 2026 and 24,992,388 shares of Common Stock were outstanding as of that date. The Board asks shareholders to elect seven directors, ratify Deloitte & Touche LLP as auditor, approve an advisory say-on-pay, and vote on charter amendments to adopt simple majority voting and a 25% special-meeting ownership threshold, plus related adjournment and a non-binding stockholder proposal to adopt a 10% special-meeting right.
The proxy discloses executive pay design and 2025 outcomes: $2,231.3M revenue, reported Adjusted EBITDA $403.8M (final MIP result $425.0M) and Free Cash Flow reported $99.9M (final MIP result $125.0M), which funded the 2025 MIP at 150%. CEO Vivek Jain had 2025 base salary $775,000 and received performance and time-based RSUs.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported compensation-related share activity tied to performance awards. He exercised performance-based restricted stock units and restricted stock units that settled into 14,648 shares of Common Stock, with no purchase or exercise price.
These units were granted on 3/15/2023 and, after the Compensation Committee certified results on 2/11/26, the performance-based awards were earned at 117% of target. To cover tax obligations, 8,096 shares were withheld at $125.85 per share, leaving a net increase of 6,552 shares. Following these transactions, Voigtlander directly owns 46,306 shares of Common Stock.
ICU Medical Inc. executive Daniel Woolson, VP and GM-Infusion Capital, exercised performance-based restricted stock units into common stock. He converted 2,924 performance shares into 2,924 shares of common stock, then had 1,295 of those shares withheld to cover tax obligations at $125.85 per share. After these compensation-related transactions, he holds 24,602 shares of common stock directly, indicating a routine vesting and tax-settlement event rather than an open‑market trade.
ICU Medical Inc. Chief Information Officer Ben Sousa reported compensation-related equity activity involving Restricted Stock Units. On 2026-03-15, 1,300 Restricted Stock Units converted into an equal number of shares of Common Stock at no purchase or exercise price. In a related step, 718 shares were withheld at $125.85 per share to satisfy tax obligations, rather than being sold on the open market. Following these transactions, Sousa directly owned 5,326 shares of ICU Medical Common Stock.
ICU Medical Inc. VP and General Counsel Virginia Ruth Sanzone reported compensation-related equity activity. On March 15, 2026, she settled performance-based restricted stock units and restricted stock units that converted into 7,324 shares of Common Stock.
To cover tax obligations, 4,047 shares were withheld at $125.85 per share, resulting in a net addition of 3,277 shares. Following these transactions, she directly holds 21,907 shares of ICU Medical common stock. The PRSUs, granted on March 15, 2023, were earned at 117% of target after performance certification.
ICU Medical (ICUI) Chairman and CEO Vivek Jain reported equity award activity and related tax withholding. On March 15, 2026, performance-based restricted stock units granted on March 15, 2023 were earned at 117% of target after Compensation Committee certification, resulting in the exercise of derivative awards for 21,972 shares of common stock. To cover tax liabilities, a total of 12,145 shares of common stock were withheld at $125.85 per share, which is not an open-market sale. Following these transactions, Jain directly holds 126,833 shares of common stock and indirectly holds 152,339 shares through a trust.
ICU Medical Chief Financial Officer Brian Michael Bonnell exercised stock awards and settled related taxes in shares. He exercised performance-based restricted stock units and restricted stock units, acquiring 14,648 shares of common stock with no cash exercise price. To cover tax liabilities, 7,595 shares were withheld at $125.85 per share, a non-market disposition. After these compensation-related transactions, he directly owns 71,750 shares of ICU Medical common stock.